Keros Therapeutics board approves $5M share buyback
Alpha Vantage · Investing.com Canada · · AI-summarised by FinFlash
Keros Therapeutics' board approved a $5 million share repurchase program for its common stock. The move follows a $20 million development milestone payment from Takeda Pharmaceuticals U.S.A., triggered by first patient dosing in the ELRiSE MF clinical trial. Management can buy shares in the open market, with timing and amount subject to market conditions and contractual limits.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.